ABBV Research Update — April 29, 2026
Updated Thesis
AbbVie Inc. is a leading healthcare company specializing in drug manufacturing with a strong focus on immunology, neuroscience, oncology, and aesthetics. The company benefits from a durable competitive moat driven by blockbuster drugs such as Skyrizi and Rinvoq, which are experiencing rapid growth and offsetting declines from Humira due to biosimilar competition.
The investment grade as of this refresh is C — average business quality. High-tier business, expensive valuation with 11% upside to $219.51 fair value
Key Metrics at a Glance
- Revenue growth: +10.0% year over year
- Net margin: 6.9%
- Forward P/E: 83.3x
- Fair value upside: +11.0% to our estimate of $220
Current price: $197.69
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. AbbVie Inc. remains in our covered universe with a average-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full ABBV research →](/stocks/ABBV)